Kornimate/medical-research-clean huggingface dataset:
effectiveness and safety of convalescent plasma therapy on covid-19 patients with acute respiratory distress syndrome

Conditions: COVID; Acute Respiratory Distress Syndrome

Summary: corona virus disease 2019 (covid-19) has been declared as a pandemic by the world health organization (who). according to who report on march 31st 2020, globally covid-19 have infected over 750,000 people and caused over 36,000 deaths with case fatality rate of 4.85%. in indonesia, covid-19 have infected 1,414 people and caused 122 deaths with case fatality rate of 8.63%. in severe cases, covid-19 causes complications, such as acute respiratory distress syndrome (ards), sepsis, septic shock, and multi-organ dysfunction syndrome (mods), where age and comorbid illnesses as a major factor to these complications. up to this point there are several promising therapies for covid-19 but is not yet recommended and in need of further research. the use of convalescent plasma has been approved by the us food and drug administration (fda) through the scheme of emergency investigational new drug (eind). this method has been used as the treatment in several outbreak or plague cases over the years, such as the flu epidemic in 1918, polio, measles, mumps, sars (severe acute respiratory syndrome), evd (ebola virus disease) and mers (middle-eastern respiratory syndrome) and this treatment shows better outcome. several case report on the use of convalescent plasma for covid-19 patients with ards and mechanical ventilation has been reported and shows promising outcome. nevertheless, larger and multicenter research need to be done to assess and evaluate the effectiveness and safety of convalescent plasma therapy on for covid-19 patients with ards.


Eligibility criteria:
inclusion criteria: * patients aged more than equal to 18 years. * covid-19 confirmed by reverse transcriptase-polymerase chain reaction (rt-pcr) * having severe pneumonia. * pao2 / fio2 \<300. exclusion criteria: * contraindication to blood transfusions (fluid overload, history of anaphylaxis of blood products) * multiple and severe organ failure, hemodynamically unstable * other uncontrolled infections * disseminated intravascular coagulation (dic) which requires a replacement factor/ffp * hemodialysis patients or crrt (continuous renal replacement therapy) * active intracranial bleeding * significant myocardial ischemia * receiving tocilizumab treatment
endotracheal tube placement in neonatal intubation

Conditions: Neonatal Respiratory Failure

Summary: endotracheal intubation is a frequent procedure performed in neonates with respiratory distress. clinicians use different methods to estimate the intubation insertion depth. in this study, the investigators aimed to compare the two different methods (kilogram + 6 cm and nasal septum-tragus length (ntl) + 1 cm) used to determine the endotracheal intubation insertion depth.

endotracheal intubation is a frequent procedure performed in neonates with respiratory distress. the ideal location of the tube is between the top of the 1st thoracic vertebra and the bottom of the 2nd thoracic vertebra in the x-ray. clinicians use different methods to estimate the intubation insertion depth. in this study, investigators aimed to compare the two different methods (kilogram+6 cm and nasal septum-tragus length (ntl)+ 1 cm) used to determine the endotracheal intubation insertion depth. in this multicentre randomized prospective study, infants who had intubation indications in neonatal intensive care unit will be enrolled. the intubation tube will be fixed at the lip level using the tochen formula (group 1) or the ntl+1 cm formula (group 2). the same brand endotracheal tubes will be used and after intubation the chest radiograph will be performed in the neutral position. chest x-ray will be evaluated blindly by a single radiologist in the digital environment (above t1, in place and below t2).

Eligibility criteria:
inclusion criteria:. * infants who had intubation indications (cardiopulmonary failure, respiratory distress or surfactant administration) in the neonatal intensive care unit exclusion criteria: * craniofacial, vertebral and genetic anomalies * those whose parents decline consent

Keywords: nasal septum-tragus length; newborn
comparative analysis of glaucoma screening uptake among first-degree relatives in community-based and hospital-based approaches

Conditions: Evaluate the Differences in Glaucoma Screening Uptake Among FDRs in Community and Hospital-based

Summary: in conclusion, the study shows that the hospital-based group had a significantly higher screening uptake than the community-based group, reflecting that information from ophthalmologists and registered ophthalmic nurses is more effective and well-received than that from village health volunteers. the study suggests that increasing education and support for village health volunteers could enhance screening uptake. factors influencing uptake include the age of fdrs, place of residence, education, presenting va of probands, and treatment of probands. utilizing this study's findings, spreading knowledge and training health officials at the district and sub-district levels could increase understanding of glaucoma and improve communication with the general public and at-risk groups, potentially increasing the response rate. additionally, implementing a national free screening glaucoma program for at-risk populations, both in and outside hospitals, and organizing mobile screening units at the district level could be an effective prevention strategy against permanent vision loss from glaucoma.


Eligibility criteria:
inclusion criteria: * all patients with poag who had a treatment history in the ophthalmology outpatient department of prapokklao hospital, chanthaburi province, were identified from the electronic medical record (emr) database with the 10th revision of the international statistical classification of diseases and related health problems (icd-10) " primary open angle glaucoma h40.1" between 1 january 2022 to 31 october 2022. a total of 1304 patients were included in this study. exclusion criteria: * excluding those with closed-angle glaucoma and secondary glaucoma due to other conditions such as accidents, post-surgical complications, uveitis, or congenital.

Keywords: glaucoma screening first-degree relatives community-based approach hospital-based approach familial risk factors
malignant progression of anal intra-epithelial neoplasia in a cohort of patients

Conditions: Anal AIN3; Anal Carcinoma

Summary: evaluation of the 3-years anal carcinoma (ac) incidence in patient with anal ain3 lesions, and factors associated with this ac. a retrospective cohort study will be conducted (2000-2013) followed by a prospective cohort study (starting in 2013) with new diagnoses of anal ain3 lesion. the main outcome is histology proven ac. the 3-years incidence rate of ac will be calculated. factors associated with ac will be estimated using a multivariate cox regression model.

"background : incidence of anal carcinoma (ac) is considerably increasing, but no data on risk of ac in patient with anal ain3 lesions are available, nor french recommendations about screening and treatment of anal ain3 lesions. objective : evaluation of the ac incidence in patient with anal ain3 lesions, and factors associated with this ac. population : patients with a diagnosis of anal ain3 lesion will be included and followed for 3 years. patients with past history of ac won't be included. study design : retrospective cohort study will be conducted from 2000 using diagnostic codes of anal ain3 lesion in histo-pathology departments. then a prospective cohort study will be conducted with new diagnoses of anal ain3 lesion. outcome : the main outcome is histology proven ac. ac identification can be done either by using diagnostic codes of ac in histo-pathology departments (for retrospective cases), or prospectively. statistics : the incidence rate of ac will be calculated. factors associated with ac will be estimated using a multivariate cox regression model. number of patients : 1000 number of centers : 35 length of follow-up: 3 years at least length of study : 3 years of inclusion and 3 years of follow-up at least"

Eligibility criteria:
inclusion criteria: to be included in the cohort, patients have to: - have an anal ain3 (including bowen's disease) diagnosed by histology (screening population, post-operative discovery...) * aposteriori for patients with a history of anal ain3 complicated or not by an anal cancer. these cases will be identified from data bases of anatomopathology laboratories in hospitals since january 1st 2000. * at the diagnostic for the new anal ain3 units care involved in the study are those involved in the follow-up of patients with anal pathologies en france, especially anal cancer. samples are analyzed by the laboratories of anatomopathology of the hospitals where the patients are diagnosed. these points make the histological data bases reliable and allow clearly identifying cases of anal ain3 retrospectively since 2000. taking in account the number and quality of the units care involved in the study and the way cases are identified, we think our recruitment will be exhaustive in france, to limit selection bias. - patient's non opposition to study exclusion criteria: * history of anal carcinoma without any history of anal ain3 lesion * impossible follow-up for the duration of the study (3 years or more) * patient aged under 18

Keywords: anal carcinoma ain3 cohort study
lithium clearance in patients with high risk of acute kidney injury

Conditions: Acute Kidney Injury

Summary: renal lithium clearance is hypothesized to be a useful indicator of renal tubular function. in this study lithium clearance will be monitored in patients with sepsis associated acute kidney injury and in healthy controls.

lithium is almost completely reabsorbed in the proximal tubule in parallel with sodium and water. what is not reabsorbed here is assumed to be fully excreted in urine, giving a reasonably accurate measurement of sodium reabsorption in the proximal tubule. endogenous lithium clearance will be measured by inductively coupled plasma mass spectrometry (icp-ms). the gomez equations will be applied to calculate efferent arteriolar resistance, afferent arteriolar resistance, glomerular hydrostatic pressure, glomerular filtration pressure, and glomerular oncotic pressure. n-acetyl-β-d glucosaminidase (nag) and ngal, markers of tubular injury, will be measured by a spectrophotometric method using a commercially available kit. routine blood and urine analyses will be performed at the diagnostic clinic laboratory, university hospital of north norway, tromsø.

Eligibility criteria:
inclusion criteria sepsis associated acute kidney injury: * sepsis diagnosed or suspected * age \>18 years inclusion criteria healthy controls: * previously healthy individuals * age \>18 years exclusion criteria: oliguria or renal impairment due to other causes than sepsis. pregnancy or breast-feeding.
open-label extension of tocilizumab in subjects with generalized myasthenia gravis

Conditions: Myasthenia Gravis, Generalized

Summary: to evaluate the safety and efficacy of tocilizumab in the treatment of generalized myasthenia gravis (gmg) as an extension study for the participants who previously completed study tmg(nct05067348).

tmg-e was an extension study designed to provide the participants who completed study tmg an opportunity to receive tocilizumab and collect clinical data to provide long-term safety and efficacy information on tocilizumab in participants with gmg. after receiving blinded study treatment (tocilizumab or placebo) in study tmg for 16 weeks, participants were eligible to enroll in the tmg-e extension study. participants were to enter study tmg-e within 8 weeks after completing their week 16 visit in study tmg. study tmg-e consisted of an open-label treatment phase up to 16 weeks.

Eligibility criteria:
inclusion criteria: 1. participant has completed study tmg. 2. participant has given written informed consent. 3. mg-adl score ≥ 5 points, or a decrease of ≤ 3 points relative to the baseline mg-adl of the tmg study exclusion criteria: 1. participants had clinically relevant active infections (such as sepsis, pneumonia, or abscess) or severe infections (resulting in hospitalization or requiring antibiotic treatment) in the past 4 weeks; 2. those with high-risk tuberculosis infection, acquired tuberculosis infection, and chronic hepatitis after the tmg study; 3. planned thymectomy during rcp; 4. received ivig or plasma exchange in the past 4 weeks; 5. any medical condition or circumstances that, in the opinion of the investigator, might have interfered with the participant's participation in the study, posed any added risk for the participant, or confounded the assessment of the participants.

Keywords: generalized myasthenia gravis tocilizumab open-label
study of bimatoprost solution in increasing eyelash prominence in african americans with eyelash hypotrichosis

Conditions: Hypotrichosis

Summary: this study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in self-identified african american/ethnic black subjects exhibiting hypotrichosis of the eyelashes (inadequate or not enough eyelashes).


Eligibility criteria:
inclusion criteria: * african american/ethnic black * adults at least 18 years of age * eyelash prominence assessment of minimal or moderate exclusion criteria: * subjects with uneven lashes or longer on one side than the other * any eye disease or abnormality * eye surgery * severe hyperpigmentation around the eye * eyelash implants * eyelash extension application * any use of eyelash growth products within 6 months * any use of prescription eyelash growth products * treatments that may affect hair growth * requiring eye drop medications for glaucoma
aetiology of asymmetrical hearing loss: a retro-spective study thesis submitted for partial fulfillment of master degree in audio-vestibular medicine

Conditions: Asymmetrical Hearing Loss

Summary: hearing loss maybe: -symmetrical: in which the severity and pattern of hearing loss are the same in each ear. or -asymmetrical: is defined as binaural difference in bone conduction thresholds of \>10 db at two consecutive frequencies or \>20 db at one frequency (0.25-8.0 khz), poorer speech perception will often accompany poorer hearing and may be the reason for the patient's presentation .unilateral or asymmetrical sensorineural hearing loss is important to discern, as it is an important risk factor for auditory nerve tumors (i.e. vestibular schwannoma) which is a life threatening condition, and in such cases further investigation is required (i.e. mri scan) unless there is a known reason for the asymmetry, several reports have recommended that further evaluation, especially expensive imaging studies, be conducted to rule out acoustic tumors when ahl is present


Eligibility criteria:
inclusion criteria: * age: 6 years old and more. * sex: male and female. exclusion criteria: * age: less than 6 years old. * patients with symmetrical hearing loss.
collection of samples and clinical data from patients with amyloid diseases

Conditions: Multiple Myeloma

Summary: rationale: collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. purpose: this research study is collecting samples from patients with amyloid diseases

objectives: * to establish and maintain a database of clinical material (i.e., blood, urine, and tissue) and information on patients with amyloid diseases. outline: blood, urine, tissue, and bone marrow samples are collected during standard laboratory evaluations to maintain a repository of biospecimens in the gerry amyloid research laboratory, to permit the correlation of clinical results with measured biological events, and for future research studies. bone marrow rna samples are examined for immunoglobulin light-chain gene sequences and amino acids by polymerase chain reaction and positional cloning. blood serum and urine samples are evaluated for amyloid protein stability by high-resolution calorimetry, isothermal-titration calorimetry, and far- and near-uv circular dichroism and fluorescence spectroscopy. urine samples are also examined for post-translational modifications (e.g., glycosylation, sulfation, and cross-linking) to identify common features unique to amyloid proteins. tissue samples are analyzed for biochemical and biophysical properties and for post-translational modifications in light chains. quality of life is assessed by the 36-item short form survey (sf-36).

Eligibility criteria:
inclusion criteria: disease characteristics: * diagnosis or suspicion of amyloidosis patient characteristics: * referred to the amyloid treatment and research center at boston university medical center prior concurrent therapy: * not specified exclusion criteria: none

Keywords: primary systemic amyloidosis
assessment of pain, occupational fatigue, sleep and quality of life in nurses

Conditions: Pain in A Joint, Multiple Sites

Summary: the aim of the study is to evaluate the pain, occupational fatigue, sleep and quality of life in nurses and the relationships between them. 102 participants working as nurses were included in the study. data on age, gender, height, weight, working year in the profession, weekly working hours, hand dominance, diagnosed diseases and marital status of the participants were collected. subsequently, the questions included in the nordic musculoskeletal questionnaire, occupational fatigue / burnout / recovery scale (ofer), sleep hygiene index (shi) and world health organization quality of life scale (whoqol-bref) questionnaires were answered by the participants.

nordic musculoskeletal questionnaire: it is a scale that evaluates whether symptoms of pain, pain and discomfort have been experienced in the neck, shoulder, elbow, hand-wrist, waist, back, hip-thigh, knee-foot-ankle regions during the last 12 months and whether ordinary indoor and outdoor activities are hampered by these symptoms and whether there has been pain in the mentioned body areas for the last 7 days. it consists of 27 items and each item is answered as yes / no. occupational fatigue exhaustion recovery scale: it is a scale developed to measure occupational fatigue. it consists of 15 items in total and 3 sub-dimensions evaluating chronic fatigue (questions 1-5), acute fatigue (questions 6-10) and recovery (questions 11-15). each item is scored between 0-6 points (0 = strongly disagree, 1 = disagree, 2 = somewhat disagree, 3 = neither agree nor disagree, 4 = slightly agree, 5 = agree, 6 = strongly agree) by the participants. high scores in the chronic and acute fatigue sub-dimensions mean higher occupational fatigue, and higher scores in the recovery sub-dimension mean better recovery between working periods. sleep hygiene index: it is a scale that evaluates sleep hygiene. the frequencies of sleep hygiene-related behaviors are questioned in a total of 13 items with a likert-type scale where each item is scored between 0 and 4 (0 = never, 1 = rarely, 3 = sometimes, 4 = often, 5 = always). higher scores indicate worse sleep hygiene. whoqol-bref-tr: it is a scale that evaluates the well-being of individuals in 4 sub-areas in which physical health, psychological status, social relations and environmental conditions are questioned, and their general quality of life and health status with one question. each item is scored on a 1-5 likert-type scale. sub-domain scores represent the quality of life in their field independently of each other. higher scores indicate better quality of life.

Eligibility criteria:
inclusion criteria: * being over 18 years old * working as a nurse exclusion criteria: * being under the age of 18 * having a history of serious trauma and orthopedic surgery in the last 1 year * having a chronic severe internal and neurological disease
collagen paste vs mucosal advancement flap for fia

Conditions: Fistula-in-ano

Summary: the treatment for fistula-in-ano (fia) remains a challenge to general and colorectal surgeons worldwide. a variety of surgical treatments have been described for high anal fistulas, but none offers the panacea of fistula eradication with guaranteed preservation of continence. this study compares collagen paste injection to mucosal advancement flap for the treatment of fistula-in-ano.

rectal advancement flaps have been advocated as a means of closing high fistulas with preservation of the external sphincter muscle. with this technique, it shows promising results with success rate of approximately 60%. however, complications have been reported, in particular with a change of continence in 30-35% of patients. collagen paste is a novel sphincter-preserving method for fistula closure. permacol (medtronic, usa) is a sterile acellular cross-linked porcine dermal collagen matrix suspension. the paste-like suspension form a matrix that accelerates neovascularization, cellular infiltration which promotes healing and fistula closure. the theoretical benefits of paste form compared to previous collagen plug design is that the collagen can moulded into the fistula cavity or tract. this allows better tissue contact with the collagen thus improves healing and reduces the chance of dislodgement. limited data is available to date. success rates of collagen paste range from 47.6% to 63%. hence it has a potential to be the first-line treatment for high fia with low complication rates and without causing disruption to the anal sphincter complex.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of high cryptoglandular fistula-in-ano. * patients must have undergone a prior eua to characterise the nature of the fistula. * the fistula tract should be ≥ 2 cm in length. * only a single internal fistula opening should be present at eua, such that the fistula is suitable for treatment by insertion of a seton drain. * patients must have been treated with a draining seton for a minimum period of 6 weeks prior to randomisation. * patients must be aged ≥ 18 years and able to provide informed consent. * fistulas must be of cryptoglandular aetiology. exclusion criteria: * unable/unwilling to provide informed consent. * contraindication to general anaesthesia or spinal anaesthesia. * low trans-sphincteric fistulas. * non-cryptoglandular fistulas (e.g. crohn's disease, obstetric, irradiation, malignant, etc.). * other perineal fistulas (e.g. rectovaginal fistulas, pouch-vaginal fistulas, etc.). * complex disease in which more than one internal fistula opening is present and requiring concurrent insertion of more than one fistula plug. * clinical evidence of active perianal sepsis. in the event that there is disagreement between clinical and radiological assessment of active sepsis/collection, the clinical opinion will prevail. * cultural or religious objection to the use of pig tissue. * absolute contraindication to magnetic resonance imaging (mri) (e.g. cardiac pacemaker). * patients with recurrent anal fistulas previously treated with a fistula plug.